Interim report Q1 2025

08.05.25 07:58 Uhr

Werte in diesem Artikel
Aktien

59,30 EUR 2,10 EUR 3,67%

Strong start to the year and confirmed full-year outlook

Ester Baiget, President & CEO:  "We delivered strong sales growth and earnings in the first quarter, with all four sales areas showing double-digit growth. Growth was driven by strong innovation especially in emerging markets, and with a continued broad pull for our solutions in developed markets. Synergies are materializing as expected and we are confirming the full-year outlook. We continue to see solid demand across the business, and our regional presence and resilient global setup enable us to respond with agility in these dynamic times”.

Wer­bung

  • Strong organic sales growth of 11% including ~1pp from price. All sales areas with double-digit organic sales growth. Emerging markets organic sales growth at 15% and developed markets at 9%.
  • Adjusted EBITDA margin at 38.3%, up by 310bps.
  • Adjusted net profit increased by 27%.
  • NIBD/EBITDA at 1.1x.
  • Announcement on February 11 to acquire dsm-firmenich’s part of the feed enzyme alliance at a EUR 1.5bn cash consideration, expected to close in the second quarter.
  • Andrew Taylor announced on April 22 as new EVP Food & Beverages, joining the company no later than September 1, 2025.
  • 2025 outlook maintained: 5-8% organic sales growth (6-9% excluding the exit from certain countries) and an adjusted EBITDA margin between 37-38% despite current currency headwinds.


Please read the full announcement in PDF

Attachment


Ausgewählte Hebelprodukte auf Novozymes A-S (B)

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Novozymes A-S (B)

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Novozymes A-S (B)

Wer­bung

Analysen zu Novozymes A-S (B)

DatumRatingAnalyst
17.10.2012Novozymes holdDeutsche Bank AG
03.09.2012Novozymes buyING
28.08.2012Novozymes overweightMorgan Stanley
09.08.2012Novozymes overweightMorgan Stanley
22.06.2012Novozymes overweightMorgan Stanley
DatumRatingAnalyst
03.09.2012Novozymes buyING
28.08.2012Novozymes overweightMorgan Stanley
09.08.2012Novozymes overweightMorgan Stanley
22.06.2012Novozymes overweightMorgan Stanley
17.11.2011Novozymes overweightMorgan Stanley
DatumRatingAnalyst
17.10.2012Novozymes holdDeutsche Bank AG
15.10.2010Novozymes holdVontobel Research
13.08.2010Novozymes holdVontobel Research
DatumRatingAnalyst
05.05.2005Novozymes: Sector UnderperformVontobel

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novozymes A-S (B) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen